ACADIA Pharmaceuticals
ACAD
17.11
-0.48
-2.73%
ACADIA Pharmaceuticals
US · ACAD
#2404 by market cap
Listed 1970
17.11
-0.48
-2.73%
Periodic snapshot; not a real-time feed.
· 2026-11-20 19:30
Recent news
-
A Quick Look at Today's Ratings for ACADIA Pharmaceuticals(ACAD.US), With a Forecast Between $23 to $38Market Newswire · 2026/11/6
-
Company notice
AMA Group Ltd: GUD: Investor Presentation - ACAD Division from AMA GroupN/A · 2020/11/19
-
Rating change
Analysts Are Bullish on These Healthcare Stocks: ACADIA Pharmaceuticals (ACAD), Kyverna Therapeutics, Inc. (KYTX)TipRanks · 2026/9/25
-
Rating change
RBC Capital Maintains ACADIA Pharmaceuticals(ACAD.US) With Buy Rating, Cuts Target Price to $36Market Newswire · 2026/10/8
-
BMO Capital Maintains ACADIA Pharmaceuticals(ACAD.US) With Buy Rating, Maintains Target Price $34Market Newswire · 2026/11/11
-
Company notice
GUD Holdings Ltd: AMA: Completion of ACAD sale and operating updateN/A · 2020/12/31
-
Rating change
A Quick Look at Today's Ratings for ACADIA Pharmaceuticals(ACAD.US), With a Forecast Between $31 to $36Market Newswire · 2026/9/26
-
Company notice
AMA Group Ltd: Completion of ACAD sale and operating updateN/A · 2020/12/31
-
Rating change
BofA Securities Maintains ACADIA Pharmaceuticals(ACAD.US) With Buy Rating, Maintains Target Price $31Market Newswire · 2026/10/9
-
Rating change
Needham Maintains ACADIA Pharmaceuticals(ACAD.US) With Buy Rating, Maintains Target Price $35Market Newswire · 2026/10/19
-
Rating change
Analysts' Top Healthcare Picks: Kyverna Therapeutics, Inc. (KYTX), ACADIA Pharmaceuticals (ACAD)TipRanks · 2026/9/25
-
Company notice
GUD Holdings Ltd: GUD completes acquisition of ACAD BusinessesN/A · 2020/12/31
-
BofA Securities Maintains ACADIA Pharmaceuticals(ACAD.US) With Buy Rating, Announces Target Price $31Market Newswire · 2026/11/11
-
Rating change
RBC Capital Maintains ACADIA Pharmaceuticals(ACAD.US) With Buy Rating, Raises Target Price to $38Market Newswire · 2026/11/5
-
CCORF Maintains ACADIA Pharmaceuticals(ACAD.US) With Buy Rating, Raises Target Price to $38Market Newswire · 2026/11/6
-
Rating change
UBS Maintains ACADIA Pharmaceuticals(ACAD.US) With Hold Rating, Maintains Target Price $23Market Newswire · 2026/10/14
-
Rating change
UBS Downgrades ACADIA Pharmaceuticals(ACAD.US) to Hold Rating, Cuts Target Price to $23Market Newswire · 2026/10/13
-
Morgan Stanley Maintains ACADIA Pharmaceuticals(ACAD.US) With Hold Rating, Cuts Target Price to $24Market Newswire · 2026/11/13
-
Company notice
GUD Holdings Ltd: Investor Presentation - ACAD Division from AMA GroupN/A · 2020/11/19
-
Rating change
RBC Capital Maintains ACADIA Pharmaceuticals(ACAD.US) With Buy Rating, Maintains Target Price $37Market Newswire · 2026/10/6
-
Rating change
CCORF Maintains ACADIA Pharmaceuticals(ACAD.US) With Buy Rating, Maintains Target Price $36Market Newswire · 2026/9/3
-
Rating change
Deutsche Bank Maintains ACADIA Pharmaceuticals(ACAD.US) With Buy Rating, Raises Target Price to $38Market Newswire · 2026/8/25
-
BMO Capital Maintains ACADIA Pharmaceuticals(ACAD.US) With Buy Rating, Maintains Target Price $34Market Newswire · 2026/10/13
-
Rating change
A Quick Look at Today's Ratings for ACADIA Pharmaceuticals(ACAD.US), With a Forecast Between $36 to $40Market Newswire · 2026/8/25
-
Rating change
BMO Capital Initiates ACADIA Pharmaceuticals(ACAD.US) With Buy Rating, Announces Target Price $36Market Newswire · 2026/8/18
Headlines are aggregated automatically and are not independently verified or edited by our team.
Quote time 2026-11-20 19:30:06 · For reference only, not investment advice and not tailored to your situation.
ACADIA Pharmaceuticals discussion 0 comments